ARA-290 is a variant of erythropoietin which has been shown to decrease inflammatory pathways through paracrine signalling and the innate repair receptors.
Name: ARA-290; ARA290; ARA 290; Cibinetide
CAS No.: 1208243-50-8
Peptide Sequence: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
Molecular Formula: C51H84N16O21
Molecular Weight: 1257.31
Appearance: White Lyophilized powder
ARA-290 is a small peptide derived from the helix beta domain of erythropoietin (EPO).EPO haslong been know to exhibit actions beyond the stimulation of red blood cell production in bonemarrow.The glycoprotein, which is made in the kidney, has been found to stimulate blood vesselgrowth, promote cell survival, alter blood pressure, and produce neuroprotective effects in diabeticneuropathy.ARA-290 offers the neuroprotective and pain relieving effects of EPO without stimulating red blood ell production.ARA-290 has completed phase ll trials and is in preparation to enter phase ll trials for a variety of applications in diabetes and the autoimmunesarcoidosis. Right now, the peptide is of active interest for its ability to control neuropathic pain,but it is also under investigation as a potential stimulator of wound repair in chronic diabetes, asan immune modulatory drug, and as a potential treatment for systemic lupus erythematosus(lupus or SLE).
Product use: This product is only for research chemicals.
Contact: Sophia Wang
Phone:
E-mail: info@mc-biotech.com
Add: 2nd Floor,ECNU Science Park,No.1006 Jinshajiang Road, Putuo District, Shanghai
Lankecms
Lankecms